Redsense Medical (REDS) Q2 2024 earnings summary

Executive summary

• Q2 2024 marked Redsense Medical's strongest quarter ever, with net sales of KSEK 8,749, up 81% year-over-year, driven by the US market and home hemodialysis segment.

• The company is preparing to launch the Redsense Clamp, a device to enhance patient safety, with CE mark and FDA 510(k) submissions underway.

• ShapeQ GmbH increased its ownership to 20.9% during the quarter, signaling strong investor confidence.

• Leadership transition occurred as CFO Jennie Kardell was appointed acting CEO following the departure of the former CEO.

Financial highlights

• Net sales for Q2 2024 were KSEK 8,749 (4,831), an 81% increase compared to Q2 2023; H1 2024 net sales were KSEK 10,460 (11,655), a 10% decrease year-over-year.

• Gross margin improved to 62% in Q2 2024 from 27% in Q2 2023.

• EBIT for Q2 2024 was KSEK 613 (-3,045); H1 2024 EBIT was KSEK -2,043 (-3,149).

• Earnings per share in Q2 2024 were SEK 0.04 (0.21).

• Cash and cash equivalents at June 30, 2024, were KSEK 8,116 (6,966).

Outlook and guidance

• Focus remains on leveraging the US home hemodialysis market, launching the Redsense Clamp in new geographies, and obtaining regulatory approvals.

• Anticipates continued growth in the home hemodialysis segment and increased sales to US distributors.

• Preparing for CE mark and FDA 510(k) submission for the Redsense Clamp, with launch planned later in 2024.